Ide-Cel: Real-World Outcomes for Relapsed Refractory Multiple Myeloma

Opinion
Video

Panelists discuss how ide-cel, a CAR T-cell therapy, demonstrates promising real-world outcomes in patients with relapsed/refractory multiple myeloma, potentially offering a valuable treatment option for this challenging patient population.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content